

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-26. (Canceled)

27. (Currently Amended) A method for enhancing the efficacy of a ~~non-polynucleic acid based cytotoxic or anti-neoplastic~~chemotherapeutic agent for a cancer cell, said method comprising administering to a subject hyaluronan and said ~~non-polynucleic acid based cytotoxic or anti-neoplastic~~chemotherapeutic agent, wherein the hyaluronan has a molecular weight between 400,000 and 900,000 Da.

28. (Currently Amended) The method according to Claim 27, wherein the hyaluronan has a molecular weight between ~~400,000~~750,000 and 900,000 Da.

29. (Previously Presented) The method according to Claim 28, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

30. (Previously Presented) The method according to Claim 28, wherein the hyaluronan has a molecular weight of 890,000 Da.

31. (Previously Presented) The method according to Claim 28, wherein the hyaluronan has a molecular weight of 750,000 Da.

32. (Currently Amended) The method according to Claim 28, wherein the ~~non-polynucleic acid based cytotoxic or anti-neoplastic~~chemotherapeutic agent is selected from

the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide or combinations thereof.

33. (Currently Amended) A method for enhancing the efficacy of a ~~non-polynucleic acid-based cytotoxic or anti-neoplastic~~chemotherapeutic agent for a cancer cell, said method comprising administering to a subject a composition consisting essentially of hyaluronan and said ~~non-polynucleic acid-based cytotoxic or anti-neoplastic~~chemotherapeutic agent, wherein the hyaluronan has a molecular weight between 400,000 and 900,000 Da.

34. (Currently Amended) The method according to Claim 33, wherein the hyaluronan has a molecular weight range between ~~400~~750,000 and 900,000 Da.

35. (Previously Presented) The method according to Claim 34, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

36. (Previously Presented) The method according to Claim 34, wherein the hyaluronan has a molecular weight of 890,000 Da.

37. (Previously Presented) The method according to Claim 34, wherein the hyaluronan has a molecular weight of 750,000 Da.

38. (Currently Amended) The method according to Claim 34, wherein the ~~non-polynucleic acid-based cytotoxic or anti-neoplastic~~chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

39. (Currently Amended) A method for overcoming acquired resistance of cancer cells to a ~~non-polynucleic acid-based cytotoxic or anti-neoplastic~~chemotherapeutic agent, said method comprising administering to a subject having said resistant cancer cells a hyaluronan

and said ~~non-polynucleic acid-based cytotoxic or anti-neoplastic~~chemotherapeutic agent, wherein the hyaluronan has a molecular weight between 400,000 and 900,000 Da.

40. (Currently Amended) The method according to Claim 39, wherein the hyaluronan has a molecular weight range between 400750,000 and 900,000 Da.

41. (Previously Presented) The method according to Claim 40, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

42. (Previously Presented) The method according to Claim 40, wherein the hyaluronan has a molecular weight of 890,000 Da.

43. (Previously Presented) The method according to Claim 40, wherein the hyaluronan has a molecular weight of 750,000 Da.

44. (Currently Amended) The method according to Claim 40, wherein the ~~non-polynucleic acid-based cytotoxic or anti-neoplastic~~chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide

45. (Currently Amended) A pharmaceutical composition consisting essentially of a ~~non-polynucleic acid-based cytotoxic or anti-neoplastic~~chemotherapeutic agent and hyaluronan, wherein the hyaluronan has a molecular weight between 400,000 and 900,000 Da.

46. (Currently Amended) The pharmaceutical composition of Claim 45, wherein the hyaluronan has a molecular weight range between 400750,000 and 900,000 Da.

47. (Previously Presented) The pharmaceutical composition of Claim 46, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

48. (Previously Presented) The pharmaceutical composition of Claim 46, wherein the hyaluronan has a molecular weight of 890,000 Da.

49. (Previously Presented) The pharmaceutical composition of Claim 46, wherein the hyaluronan has a molecular weight of 750,000 Da.

50. (Currently Amended) The pharmaceutical composition of Claim 46, wherein the ~~non-polynucleic acid-based cytotoxic or anti-neoplastic~~chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

51. (Currently Amended) A pharmaceutical composition comprising ~~non-polynucleic acid-based cytotoxic or anti-neoplastic~~chemotherapeutic agent and hyaluronan having molecular weight of modal molecular weight of 890,000 Da.

52. (Previously Presented) The pharmaceutical composition of Claim 51, wherein the hyaluronan has molecular weight 890,000 Da.

53. (New) The method according to any one of claims 27, 33, and 39, wherein the hyaluronan has a molecular weight between 750,000 and 890,000 Da.

54. (New) The method according to any one of claims 27, 33, and 39, wherein the hyaluronan has a molecular weight between 890,000 and 900,000 Da.

55. (New) The pharmaceutical composition according to claim 45, wherein the hyaluronan has a molecular weight between 750,000 and 890,000 Da.

56. (New) The pharmaceutical composition according to claim 45, wherein the hyaluronan has a molecular weight between 890,000 and 900,000 Da.